CDT Equity Inc. (CDT): auditor change — Conduit Pharmaceuticals restates Q1 and Q2 2024 financials; reclassifies deferred commission to current liability

CDT Equity Inc.

Previously issued unaudited financials for Q1 and Q2 2024 should no longer be relied upon due to reclassification error.
Restatement reclassifies deferred commission payable from long-term to current liability; no impact on total liabilities.
Company will file amendments to its Q1 and Q2 2024 Forms 10-Q to correct the balance sheet classification.
Discussions with auditor Marcum LLP and Audit Committee led to the non-reliance determination on November 12, 2024.

item 4.02

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

CDT Equity Inc. reported that prior financial statements should not be relied upon.

Action: non reliance

Exact text from the filing

the Company’s previously issued unaudited financial statements, and notes related thereto, for the Subject Periods (as defined below) should no longer be relied upon

View on SEC.gov

8 auditor changes filed in the last 30 days. Browse all auditor changes →

CDT Equity Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-046068

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.